Regarding the infectious risk, while the need of tuberculosis and hepatitis B screening is currently debated, the varicella zoster virus (VZV) antibody titer is recommended, and, if negative, the completion of the vaccination series is advised before starting the therapy with S1P modulators. This evidence concerns the gene MBTPS1 and hepatitis B virus infection.